drugset
drugset / Trial / NCT05076617

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617 ↗

Phase 3 Enrolling by invitation 300 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Timeline

Start
2022-02-03
Primary completion
2028-11-30
Completion
2028-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule — Inhaled

Indications

epilepsy syndrome